ReviewJournal of nanobiotechnology2026
Exosome-mimetic nanocarriers in cancer diagnosis and drug delivery: engineering strategies, functional biomimicry, safety considerations, and clinical translation.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains one of the leading causes of mortality worldwide, driving the development of advanced drug delivery systems to improve therapeutic selectivity and overcome the complex defense mechanisms of malignant cells. Exosome-mimetic nanocarriers (EMNs) have emerged as an advanced biomimetic platform for cancer diagnosis and targeted drug delivery, combining the biological functionality of natural exosomes with the manufacturing flexibility and scalability of synthetic nanocarriers. This review analyzes the composition, design, and architecture of EMNs, as well as their applications in cancer drug delivery, drawing on fundamental concepts of pharmaceutical technology to provide a translational perspective. It also includes a dedicated section on cancer diagnosis and theranostic platforms, as well as a critical analysis of recent technological advancements in exosome-mimetic systems. Although the clinical translation of natural exosomes remains limited, emerging evidence suggests that engineered EMNs offer improved scalability, reproducibility, and therapeutic versatility. Recent studies highlight their potential to overcome key limitations of natural vesicles, positioning them as promising candidates for future clinical translation and commercialization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.